Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

At second interim analysis, addition of 2 years of adjuvant palbociclib to adjuvant endocrine therapy did not improve invasive disease-free survival vs adjuvant endocrine therapy alone (n=5760; 3-year disease-free survival 88.2% vs 88.5%; HR 0.93 [95% CI 0.76–1.15]; p=0.51).

Source:

The Lancet Oncology